natgillin/translations-raw huggingface dataset:
I alle studier med crizotinib hos patienter med enten ALK-positiv eller ROS1-positiv NSCLC var mediantiden indtil grad 1 eller 2 aminotransferasestigning 23 dage. 
Across studies with crizotinib in patients with either ALK-positive or ROS1-positive NSCLC, median time to onset of increased Grade 1 or 2 transaminases was 23 days.
Efter dosering med crizotinib 200 mg to gange dagligt havde patienter med moderat nedsat leverfunktion (N=8) øget systemisk crizotinib-eksponering sammenlignet med patienter med normal leverfunktion (N=9) ved det samme dosisniveau, med geometriske middelværdier for AUCdaily og Cmax på henholdsvis 150% og 144%. 
Following crizotinib 200 mg twice daily dosing, patients with moderate hepatic impairment (N=8) showed higher systemic crizotinib exposure compared to patients with normal hepatic function (N=9) at the same dose level, with geometric mean ratios for AUCdaily and Cmax of 150% and 144%, respectively.
Administration af gentagne doser crizotinib (250 mg 1 gang dagligt) sammen med gentagne doser itraconazol (200 mg 1 gang daglig), en stærk CYP3A-hæmmer, medførte en stigning i crizotinib steady state AUCtau og Cmax-værdier, der var henholdsvis cirka 1,6 og 1,3 gange større end dem, der ses, når crizotinib administreres alene. 
Coadministration of repeated doses of crizotinib (250 mg once daily) with repeated doses of itraconazole (200 mg once daily), a strong CYP3A inhibitor, resulted in increases in crizotinib steady-state AUCtau and Cmax, that were approximately 1.6-fold and 1.3-fold, respectively, those seen when crizotinib was administered alone.
Medicinen nævnt herunder kan nedsætte virkningen af XALKORI 
The following medicines may reduce the effectiveness of XALKORI:
YDRE KARTON TIL BLISTER 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR BLISTER
• Clonidin, guanfacin, til behandling af for højt blodtryk. 
• Clonidine, guanfacine, used to treat hypertension.
Behandling af patienter, der udvikler symptomatisk bradykardi, fremgår af afsnittene Dosisjustering og Bivirkninger (se pkt. 
For management of patients who develop symptomatic bradycardia, see Dose Modification and Undesirable Effects sections (see sections 4.2 and 4.8).
4.4) med en maksimal middelreduktion på 17,8 slag i minuttet (bpm) efter 8 timer på dag 1 i cyklus 2. 
In addition, a decrease in heart rate was found to be associated with increasing crizotinib plasma concentration (see section 4.4), with a maximum mean reduction of 17.8 beats per minute (bpm) after 8 hours on Cycle 2 Day 1.
• Langsom puls. 
• Reduced heart rate.
Derfor bør crizotinib anvendes med forsigtighed på grund af risiko for udtalt bradykadi, når det anvendes sammen med lægemidler, der kan give bradykardi (fx non-dihydropyridin calciumantagonisterså som verapamil og diltiazem, beta-blokkere, clonidin, guanfacin, digoxin, mefloquin, acethylcholinesterase, pilocarpin) (se pkt. 
Bradycardia has been reported during clinical studies; therefore, use crizotinib with caution due to the risk of excessive bradycardia when used in combination with other bradycardic agents (e.g., non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, beta-blockers, clonidine, guanfacine, digoxin, mefloquine, anticholinesterases, pilocarpine) (see sections 4.2 and 4.4).
Efter markedsføringen er der blevet rapporteret om tilfælde af gastrointestinal perforation med dødelig udgang ved brug af crizotinib (se pkt. 
There were reports of fatal cases of gastrointestinal perforation during post-marketing use of crizotinib (see section 4.4).
Dermed kan crizotinib potentielt øge plasmakoncentrationen af lægemidler, som er substrater for P-gp, når disse administreres samtidig (se pkt.4.5). 
Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are substrates of P-gp (see section 4.5).
QT-intervallet bør måles, når denne kombination anvendes (se pkt. 
A monitoring of the QT interval should be made in case of combinations of such medicinal products (see sections 4.2 and 4.4).
Nyrecyste n (3%) Forhøjet blodkreatinin o (8%) 
Renal cystn (3%) Blood creatinine increasedo (8%)
De demografiske og sygdomsrelaterede karakteristika for den samlede studiepopulation var 62% kvinder, medianalder 53 år, Eastern Cooperative Oncology Group (ECOG) -performancestatus ved baseline 0 eller 1 (95%), 51% hvide og 46% asiatere, 4% var nuværende rygere, 32% var tidligere rygere, og 64% havde aldrig røget. 
The demographic and disease characteristics of the overall study population were 62% female, median age of 53 years, baseline Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (95%), 51% White and 46% Asian, 4% current smokers, 32% past smokers and 64% never smokers.
Uanset kausalitet sås der forlænget QT-interval af grad 3 eller 4 hos 27 (1,6%) ud af 1.722 patienter (se pkt. 
All-causality Grade 3 or 4 Electrocardiogram QT prolonged was reported in 27 (1.6%) out of 1722 patients (see sections 4.2, 4.4, 4.5 and 5.2).
Hvis der ikke findes samtidigt administrerede lægemidler, der bidrager til bardykardi, eller hvis samtidigt administrerede lægemidler ikke seponeres eller sættes ned i dosis, genoptages behandlingen med nedsat dosis c XALKORI efter forbedring til grad ≤ 1 eller til hjertefrekvens på 60 eller derover 
If no contributing concomitant medicinal product is identified, or if contributing concomitant medicinal products are not discontinued or dose modified, resume at reduced dosec upon recovery to Grade ≤1 or to heart rate 60 or above
Kontakt lægen, før du tager XALKORI: 
Warnings and precautions Talk to your doctor before taking XALKORI:
Der er mest information om patienter med en særlig celletype af ALK-positiv ikke-småcellet lungekræft (adenokarcinom), og der er begrænset information om patienter med andre celletyper. 
Most of the available information is available in patients with some specific histology type of ALK-positive NSCLC (adenocarcinoma) and limited information is available in the other histologies.
Indehaveren af markedsføringstilladelsen skal have undervisningsmateriale godkendt af myndighederne i det enkelte medlemsland. 
The MAH shall agree the content and format of the educational material with the National Competent Authority.
Forlænget QT-interval er set i kliniske studier med crizotinib. 
In clinical studies, prolonged QT interval was observed with crizotinib.
Data for effekt ved ROS1-positiv fremskreden NSCLCfra studie 1001 Effektivitetsparameter 
ROS1-positive advanced NSCLC efficacy results from Study 1001 Efficacy Parameter
Lægemidler, som kan nedsætte plasmakoncentrationen af crizotinib Administration af gentagne doser crizotinib (250 mg 2 gange dagligt) sammen med gentagne doser af rifampicin (600 mg 1 gang dagligt) en kraftig CYP3A4-induktor, medførte et fald i crizotinib steady state AUCtau og Cmax-værdier på henholdsvis 84% og 79%, sammenlignet med når crizotinib administreres alene. 
Coadministration of repeated doses of crizotinib (250 mg twice daily) with repeated doses of rifampicin (600 mg once daily), a strong CYP3A4 inducer, resulted in 84% and 79% decreases in crizotinib steady-state AUCtau and Cmax, respectively, compared to when crizotinib was given alone.
I kliniske studier hos 1.722 patienter behandlet med crizotinib for enten ALK-positiv eller ROS1-positiv NSCLC var de hyppigste bivirkninger (≥ 3%) i forbindelse med afbrydelse af behandlingen neutropeni, aminotransferasestigning, opkastning og kvalme. 
In 1722 patients treated with crizotinib with either ALK-positive or ROS1-positive NSCLC across clinical studies, the most frequent adverse reactions (≥3%) associated with dosing interruptions were neutropenia, elevated transaminases, vomiting, and nausea.
Crizotinib skal anvendes med forsigtighed til patienter med nedsat leverfunktion (se skema 2 og pkt. 
Treatment with crizotinib should be used with caution in patients with hepatic impairment (see Table 2 and sections 4.4, 4.8 and 5.2).
Enkeltarmsstudier af ALK-positiv fremskreden NSCLC Crizotinib som monoterapi til behandling af ALK-positiv fremskreden NSCLC er blevet undersøgt i 2 multinationale, enkeltarmede studier (studie 1001 og 1005). 
The use of single-agent crizotinib in the treatment of ALK-positive advanced NSCLC was investigated in 2 multinational, single-arm studies (Studies 1001 and 1005).
En oftalmologisk undersøgelse anbefales ved vedvarende synsforstyrrelser eller hvis disse progredierer (se pkt. 
Ophthalmological evaluation is recommended if vision disorder persists or worsens in severity (see section 4.8).
Det kan være nødvendigt, at lægen undersøger dit hjerte ved hjælp af et ekg under behandlingen med XALKORI. 
Your doctor may perform electrocardiograms to check there are no problems with your heart during treatment with XALKORI.
Administration af en oral enkeltdosis crizotinib 150 mg under tilstedeværelse af ketoconazol (200 mg 2 gange dagligt), en kraftig CYP3A-hæmmer, medførte en stigning i plasmakoncentrationen af crizotinib med AUC fra starttid til uendelighed (AUCinf) og maksimal plasmakoncentration (Cmax), der var henholdsvis 3,2 og 1,4 gange større end dem, der ses, når crizotinib administreres alene. 
Coadministration of a single 150 mg oral dose of crizotinib in the presence of ketoconazole (200 mg twice daily), a strong CYP3A inhibitor, resulted in increases in crizotinib systemic exposure, with crizotinib area-under-the-plasma-concentration versus time curve from time zero to infinity (AUCinf) and maximum observed plasma concentration (Cmax) values that were approximately 3.2-fold and 1.4-fold, respectively, those seen when crizotinib was administered alone.
De hyppigste bivirkninger (≥3%, uanset kausalitet) i forbindelse med dosisreduktion var aminotransferasestigning (4%) og neutropeni (3%). 
The most frequent adverse reactions (≥3%, all-causality frequency) associated with dose reductions were elevated transaminases (4%) and neutropenia (3%).
Crizotinib påvirkede antallet af kromosomer i in vitro mikronukleus-test i kinesiske hamsterovarie-celler, og i in vitro human lymfocyt-kromosomafvigelses-test. Der er set små stigninger i strukturelle kromosomafvigelser ved cytotoksiske koncentrationer i humane lymfocytter. 
Crizotinib was aneugenic in an in vitro micronucleus assay in Chinese Hamster Ovary cells and in an in vitro human lymphocyte chromosome aberration assay.
* PFS, objektiv responsrate og responsvarighed er baseret på data ved cutoff-dato 30. marts 2012, OS er baseret på data ved cutoff-dato 31. august 2015. a. Mediantiden for PFS var 4,2 måneder (95% CI: 2,8, 5,7) for pemetrexed (HR = 0,59, p = 0,0004 for crizotinib sammenlignet med pemetrexed) og 2,6 måneder (95% CI: 1,6, 4,0) for docetaxel (HR = 0,30, p < 0,0001 for crizotinib sammenlignet med docetaxel). 
OS is based on the data cutoff date of 31 August 2015. a. The median PFS times were 4.2 months (95% CI: 2.8, 5.7) for pemetrexed (HR=0.59; p-value=0.0004 for crizotinib compared with pemetrexed) and 2.6 months (95% CI: 1.6, 4.0) for docetaxel
Samtidig behandling med potente CYP3A-induktorer, inklusive (men ikke begrænset til) carbamazepin, phenobarbital, phenytoin, rifampicin og naturlægemidler som indeholder perikon bør undgås (se pkt. 
The concurrent use of strong CYP3A inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John's wort, should be avoided (see section 4.4).
• Betændelsesagtig tilstand i lungerne Kontakt straks lægen, hvis du får åndenød især hvis du også har hoste og feber. 
Tell your doctor right away if you experience difficulty in breathing, especially if associated with cough or fever.
I kliniske studier med crizotinib hos patienter med enten ALK-positiv eller ROS1-positiv NSCLC blev grad 3 eller 4 neutropeni indberettet med hyppigheden meget almindelig (12%). 
In clinical studies with crizotinib in patients with either ALK-positive or ROS1-positive NSCLC, Grade 3 or 4 neutropenia has been very commonly (12%) reported.
Hvis der findes samtidigt administrerede lægemidler, der bidrager til bradykardi, og disse seponeres, eller deres dosis nedsættes, genoptages behandlingen med den tidligere dosis XALKORI efter forbedring til grad ≤ 1 eller til hjertefrekvens på 60 eller derover 
If contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, resume at previous dose upon recovery to Grade ≤1 or to heart rate 60 or above
I de kliniske studier med crizotinib hos patienter med enten ALK-positiv eller ROS1-positiv fremskreden NSCLC sås nedsat antal leukocytter og neutrofiler af grad 3 eller 4 hos henholdsvis 4% og 13%. 
In clinical studies of crizotinib in patients with either ALK-positive or ROS1-positive advanced NSCLC, shifts to Grade 3 or 4 decreases in leukocytes and neutrophils were observed at frequencies of 4% and 13%, respectively.
• Smagsforstyrrelser. 
• Alteration in sense of taste.
Kemoterapi N=174 
Chemotherapy N=174
• Migrænemidler som ergotamin, dihydroergotamin og lignende. 
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine), used to treat migraine.
4.8 og 5.2), hvilket kan medføre øget risiko for ventrikulær takyarytmier (fx torsades de pointes) eller pludselig død. 
QTc prolongation has been observed in clinical studies in patients treated with crizotinib (see sections 4.8 and 5.2) which may lead to an increased risk for ventricular tachyarrhythmias (e.g., Torsade de Pointes) or sudden death.
Crizotinib kan derfor potentielt øge plasmakoncentrationen af samtidig administrerede lægemidler, som er substrater for OCT1 eller OCT2 (se pkt. 
Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered drugs that are substrates of OCT1 or OCT2 (see section 4.5).
Der sås lokal perirenal cysteindvækst hos nogle patienter. 
Local cystic invasion beyond the kidney was observed in some patients.
Kemoterapi N=171 
Chemotherapy N=171
XALKORI 250 mg hårde kapsler Hver hård kapsel indeholder 250 mg crizotinib. 
XALKORI 250 mg hard capsules Each hard capsule contains 250 mg of crizotinib.
Se desuden pkt. 
Keep this leaflet.
Da der er risiko for bivirkninger hos det ammede barn, bør amning ophøre under behandling med XALKORI (se pkt. 
Because of the potential harm to the infant, mothers should be advised to avoid breast-feeding while receiving XALKORI (see section 5.3).
Seponer permanent, hvis der ikke samtidigt er blevet administreret lægemidler, der bidrager til bradykardi. 
Permanently discontinue if no contributing concomitant medicinal product is identified
• Procainamid, til behandling af forstyrrelser i hjerterytmen. 
• Procainamide, used to treat cardiac arrhythmia.
Effektdata fra randomiseret fase 3-studie 1007 (samlet analysepopulation) hos patienter med tidligere behandlet ALK-positiv fremskreden NSCLC* Responsparameter 
Efficacy results from randomised Phase 3 Study 1007 (full analysis population) in patients with previously treated ALK-positive advanced NSCLC* Response Parameter
XALKORI 250 mg er en hård gelatinekapsel med pink overdel og underdel, der er mærket med sort blæk “Pfizer” på overdelen og “CRZ 250” på underdelen. 
XALKORI 250 mg is supplied as hard gelatin capsules with pink cap and body, printed with black ink “Pfizer” on the cap, “CRZ 250” on the body.
Patienterne kunne fortsætte crizotinib-behandlingen efter sygdomsprogression som defineret i RECIST, hvis patienten fortsat havde klinisk gavn af behandlingen, og det var i overensstemmelse med investigators skøn. 
Patients could continue treatment as assigned beyond the time of RECIST-defined disease progression at the discretion of the investigator if the patient was perceived to be experiencing clinical benefit.
Effektdata fra det randomiserede fase 3-studie 1014 (hele analysepopulationen) hos tidligere ubehandlede patienter med ALK-positiv fremskreden NSCLC* Responsparameter 
Efficacy results from randomised Phase 3 Study 1014 (full analysis population) in patients with previously untreated ALK-positive advanced NSCLC* Response Parameter
De demografiske og sygdomsrelaterede karakteristika var 50% kvinder, medianalder 51 år, status for ECOG-score ved baseline 0 (32%) eller 1 (55%), 61% hvide og 30% asiatere, færre end 1% var rygere, 27% var tidligere rygere, 72% havde aldrig røget, 94% metastatiske, og 98% af cancertyperne blev histologisk klassificeret som adenokarcinom. 
The demographic and disease characteristics were 50% female, median age of 51 years, baseline ECOG performance status of 0 (32%) or 1 (55%), 61% White and 30% Asian, less than 1% were current smokers, 27% former smokers, 72% never smokers, 94% metastatic, and 98% of the cancers were classified as adenocarcinoma histology.
De demografiske og sygdomsrelaterede karakteristika for den samlede studiepopulation var 56% kvinder, medianalder 50 år, ECOGperformance status ved baseline 0 (39%) eller 1 (52%), 52% hvide og 45% asiatere, 4% var nuværende rygere, 33% var tidligere rygere, og 63% havde aldrig røget, 93% havde metastaserende sygdom, og 93% af tumorerne var klassificeret som adenokarcinom. 
The demographic and disease characteristics of the overall study population were 56% female, median age of 50 years, baseline ECOG performance status 0 (39%) or 1 (52%), 52% White and 45% Asian, 4% current smokers, 33% past smokers, and 63% never smokers, 93% metastatic, and 93% of patients' tumours were classified as adenocarcinoma histology.
• Medicin mod psykose, psykisk lidelse. 
• Antipsychotics, used to treat mental illness.
Tidligere ubehandlet ALK-positiv fremskreden NSCLC - randomiseret fase 3-studie 1014 Crizotinibs virkning og sikkerhed ved behandling af patienter med ALK-positiv metastaserende NSCLC, som ikke tidligere havde fået systemisk behandling for fremskreden sygdom, blev undersøgt i et globalt, randomiseret åbent studie 1014. 
The efficacy and safety of crizotinib for the treatment of patients with ALK-positive metastatic NSCLC, who had not received previous systemic treatment for advanced disease, were demonstrated in a global, randomised, open-label Study 1014.
Det anbefales at justere crizotinibdosis hos patienter med svært nedsat nyrefunktion, som ikke kræver peritonealdialyse eller hæmodialyse (se pkt. 
An adjustment of the dose of crizotinib is recommended when administering crizotinib to patients with severe renal impairment not requiring peritoneal dialysis or haemodialysis (see sections 4.2 and 4.4).
Desuden viste den farmakokinetiske populationsanalyse med data fra studie 1001, 1005 og 1007, at CLcr ikke havde nogen klinisk betydning på crizotinibs farmakokinetik. 
In addition, the population pharmacokinetic analysis using data from Studies 1001, 1005 and 1007 indicated CLcr did not have a clinically meaningful effect on the pharmacokinetics of crizotinib.
På basis af den farmakokinetiske populationsanalyse af data fra studie 1001, 1005 og 1007 har alder ingen effekt på crizotinibs farmakokinetik. 
Based on the population pharmacokinetic analysis of data in Studies 1001, 1005 and 1007, age has no effect on crizotinib pharmacokinetics.
Sådan skal du tage XALKORI 
How to take XALKORI
Derfor bør samtidig administrering af kraftige CYP3A-hæmmere (herunder men ikke begrænset til atazanavir, ritonavir, cobicistat, itraconazol, ketoconazol, posaconazol, voriconazol, clarithromycin, telithromycin og erythromycin) undgås, medmindre den mulige fordel for patienten opvejer risikoen, i hvilket tilfælde patienten bør overvåges nøje for bivirkninger fra crizotinib (se pkt. 
Therefore, the concomitant use of strong CYP3A inhibitors (including but not limited to atazanavir, ritonavir, cobicistat, itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, and erythromycin) should be avoided.
De demografiske og sygdomsrelaterede karakteristika var 57% kvinder, medianalder 53 år, status for ECOG-score ved baseline 0/1 (82%) eller 2/3 (18%), 52% hvide og 44% asiatere, 4% rygere, 30% tidligere rygere, 66% havde aldrig røget, 92% metastatiske, og 94% af cancertyperne blev histologisk klassificeret som adenokarcinom. 
The demographic and disease characteristics were 57% female, median age of 53 years, baseline ECOG performance status of 0/1 (82%) or 2/3 (18%), 52% White and 44% Asian, 4% current smokers, 30% former smokers, 66% never smokers, 92% metastatic, and 94% of the cancers were classified as adenocarcinoma histology.
Akut nyresvigt 
Hepatic Impairment
Er du i tvivl, så spørg lægen eller apotekspersonalet. 
If you have any further questions, ask your doctor, pharmacist, or nurse.
• Colchicin, til behandling af urinsyregigt. 
• Colchicine, used to treat gout.
(QT korrigeret efter Fridericia-metoden) ≥500 ms registreret hos 34 (2,1%) af 1.619 patienter med mindst 1 ekg-vurdering efter baseline, og en maksimal forlængelse af QTcF på ≥60 ms fra baseline sås hos 79 (5,0%) af 1.585 patienter med en ekg-vurdering ved baseline og mindst 1 efter baseline. 
Across studies in patients with either ALK-positive or ROS1-positive advanced NSCLC, QTcF (corrected QT by the Fridericia method) ≥500 msec was recorded in 34 (2.1%) of 1619 patients with at least 1 postbaseline ECG assessment and a maximum increase from baseline in QTcF ≥60 msec was observed in 79 (5.0%) of 1585 patients with a baseline and at least 1 postbaseline ECG assessment.
• Behandling af voksne med ROS1-positiv fremskreden ikke-småcellet lungecancer (NSCLC) 
• The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC) 4.2 Posology and method of administration
Indeholder tilfælde indberettet indenfor klassetermerne: a) Neutropeni (febril neutropeni, neutropeni, nedsat neutrofiltal). 
a. Neutropenia (Febrile neutropenia, Neutropenia, Neutrophil count decreased).
• Prikkende, snurrende fornemmelser eller følelsesløshed i led, hænder og fødder (neuropati). 
• Neuropathy (feeling of numbness or pins and needles in the joints or extremities).
I studier med crizotinib hos patienter med enten ALK-positiv eller ROS1-positiv fremskreden NSCLC oplevede 219 (13%) af 1.722 patienter, der blev behandlet med crizotinib, bradykardi (uanset kausalitet). 
In studies with crizotinib in patients with either ALK-positive or ROS1-positive advanced NSCLC, all-causality bradycardia was experienced by 219 (13%) of 1722 patients treated with crizotinib.
Ødemer p (47%) Udtalt træthed 
Oedemap (47%) Fatigue (30%)
Printblæk 
Posology
5.2) med blindede, manuelle ekg-målinger havde 11 (21%) patienter en stigning i baseline QTcF på ≥30 til<60 ms og en patient (2%) havde en stigning i baseline QTcF på ≥60 ms. Ingen patienter havde maksimum-QTcF ≥480 ms. 
In a single arm ECG substudy (see section 5.2) using blinded manual ECG measurements 11 (21%) patients had an increase from Baseline in QTcF value ≥30 to <60 msec and 1 (2%) patient had an increase from Baseline in QTcF value of ≥60 msec. No patients had a maximum QTcF ≥480 msec.
XALKORI 200 mg hårde kapsler 
XALKORI 200 mg hard capsules
Opbevares utilgængeligt for børn. 
The indication does not cover children and adolescents.
I alle studier hos patienter med enten ALK-positiv eller ROS1-positiv fremskreden NSCLC (N=1.722) sås grad 3 eller 4 neutropeni hos 212 (12%) patienter, der blev behandlet med crizotinib. 
Across studies in patients with either ALK-positive or ROS1-positive advanced NSCLC (N=1722), Grade 3 or 4 neutropenia was observed in 212 (12%) patients treated with crizotinib.
• Træthed. 
• Constipation.
Responsvarighed Måneder g (95% CI) 
Duration of Response Monthsg (95% CI)
Virkningen af en moderat induktor herunder efavirenz eller rifabutin er ikke entydigt klarlagt. 
The effect of a moderate inducer including but not limited to efavirenz or rifabutin is not clearly established therefore, their combination with crizotinib should be also avoided (see section 4.4).
Grapefrugt og grapefrugtjuice bør undgås, da det kan øge plasmakoncentrationen af crizotinib. 
Grapefruit or grapefruit juice should be avoided since it may increase crizotinib plasma concentration; St. John's wort should be avoided since it may decrease crizotinib plasma concentration (see section 4.5).
Patienterne kunne, hvis dette var i overensstemmelse med investigators skøn, fortsætte behandlingen efter sygdomsprogression som defineret i RECIST. 
Patients could continue treatment beyond the time of RECIST-defined disease progression at the discretion of the investigator.